

Fighting an Invisible Enemy: Beginning a New Chapter in the COVID-19 Era

Editorial Comment,

The Coronavirus disease (COVID-19) pandemic has disproportionately impacted communities of color and particularly Black and Hispanic individuals.^[1,2] Combined with economic downside sparked by social distancing, the pandemic has highlighted longstanding inequities that have put the health of racial and ethnic minority groups at risk.^[1,2] History has shown that crises have a way of damaging our most vulnerable communities and COVID-19 is no different.

COVID-19 is not just a virus. The clinical disease caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the result of a complex and ongoing battle within the body between the invading virus and the body's defense system.^[3,4] Timing really matters when it comes to COVID-19 infection.

The virus enters the nose or mouth to infect the lung cells, where it can replicate first. After the virus invades, the innate immune system responds first, detecting a foreign invader and creating antibodies. For a tactical victory, all the virus has to do is delay immune response by a couple of days, and from 100 infected lung cells on day 1, tens of millions are conquered 4 or 5 days later. But if a virus subverts these early defenses, the body next needs to deploy its special operation forces that have been trained through past experiences, if they had any, to fight the specific invader that the body is facing T cells.^[3,4]

But every step of this battle can ravage the body in its way. COVID-19 disease becomes severe when viruses evade the innate immune system and replicate in the lungs. T cell can help fight the disease. But if that battle rages too large, the fortress of the body can suffer as much as from havoc wreaked by its own troops as from the infection itself.

Currently, the multidisciplinary strategy approach to prevent COVID-19 disease includes^[1,2]:

1. Pressing the need for health-care workers on the front lines
2. Well-being of staff takes top priority
3. Offering COVID-19 tests to community
4. School-aged children behavioral health screenings
5. Discovery of efficacious and safe vaccines.

Basic Science on the Clinical Front Lines: The Future Fight

There are a number of really big questions still open to investigations, including how immune people remain after infection. Immunologists are increasingly examining

how T cells learn to fight the virus effectively but not overzealously. One big area the investigators are focused is trying to understand the formation and quality of T cells' memory. They are also looking at the immune system in COVID-19 patients with long-term symptoms, the relationship of the immune system to vascular problems, and how previous infections might impact our immune response to virus.^[5,6] Further, collaborative and multidisciplinary clinical trials are pursuing how immunity develops in those with milder infections, how long-term protective immunity differs over time, and the implications of those answers for the development of future vaccines.^[7,8]

My heart is broken, but I sustained by hope to save more lives. We are getting through it!

F. Assadi

Department of Pediatrics, Division of Nephrology, Rush University Medical Center, Chicago, Illinois, USA

*Address for correspondence:
Prof. F. Assadi,*

*Department of Pediatrics, Division of Nephrology, Rush University Medical Center, 445 E. North Water Street, Suite 1804, Chicago, Illinois USA.
E-mail: fAssadi@rush.edu*

Received: 23 Jan 21 **Accepted:** 01 Feb 21

Published: 05 Jul 21

References

1. Zohner YE, Morris JS. COVID-TRACK: World and USA SARS-CoV-2 testing and COVID-19 tracking. *BioData Min* 2021;14:4.
2. Khatri UG, Pizzicato LN, Viner K, Bobyock E, Sun M, Meisel ZF, *et al.* Racial/ethnic disparities in unintentional fatal and non-fatal emergency medical services-attended opioid overdoses during the COVID-19 pandemic in Philadelphia. *JAMA Netw Open* 2021;4:e2034878.
3. Gundlapalli AV, Salerno RM, Brooks JT, Averhoff F, Peterson LR, McDonald LC, *et al.* SARS-CoV-2 serologic assay needs for the next phase of the US COVID-19 pandemic response. *Open Forum Infect Dis* 2020;8:ofaa555.
4. Oliveira EMN, Carvalho ARB, Silva JSE, Sousa Neto AR, Moura MEB, Freitas DRJ, *et al.* Analysis of scientific production on the new coronavirus (COVID-19): A bibliometric analysis. *Sao Paulo Med J* 2021;S1516-31802021005002103. doi: 10.1590/1516-3180.2020.0449.R1.01102020. Online ahead of print.
5. Razizadeh M, Nikfar M, Liu Y. Small molecule to destabilize the ACE2-RBD complex: A molecular dynamic study for potential COVID-19 therapeutics. *ChemRxiv* 2020. doi: 10.26434/chemrxiv.13377119.Preprint.
6. Pourseif MM, Parvizpour S, Jafari B, Dehghani J, Naghill B, Omid YB. A domain-based vaccine construct against SARS-CoV-2, the causative agent of COVID-19 pandemic: Development of self-amplifying mRNA and peptide vaccines.

Bioimpacts 2021;1165-84.

7. Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. *Nat Med* 2021. <https://doi.org/10.1038/s41591-021-01230-y>.
8. Ellis P, Somogyvarti F, Virok DP, Noseda M, McLean GR. Decoding Covid-19 with SARS-CoV-2 genome. *Curr Genet Med Rep* 2021;1-12. doi: 10.1007/s40142-020-00197-5. Online ahead of print.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
Quick Response Code: 	Website: www.ijpvmjournal.net/www.ijpm.ir
	DOI: 10.4103/ijpvm.ijpvm_22_21

How to cite this article: Assadi F. Fighting an invisible enemy: Beginning a new chapter in the COVID-19 era. *Int J Prev Med* 2021;12:82.